The device made its clinical debut in the US when it was used to perform a laparoscopic procedure at the Duke Center for Metabolic and Weight Loss Surgery.
The new 2.99mm Percuvance System enables procedures to be even lesser invasive and causing less trauma while matching the performance of the most commonly used 5mm laparoscopic devices in minimally invasive surgeries (MIS).
It also secured the FDA clearance as well as the CE Mark approval.
Duke Regional Hospital general surgery chief and metabolic and weight loss surgery division chief Dr. Dr. Dana D. Portenier, who performed the first clinical surgery using this new system, said: “Our experiences with the new system are consistent with other clinical studies, which showed that its handling and functionality were similar to standard 5-mm laparoscopic instrumentation.
“Further research will determine whether the system’s smaller incisions could potentially demonstrate improvements in patient pain, cosmesis, and satisfaction.”
Teleflex Surgical president and general manager John Tushar said: “Our second-generation Percuvance System represents a significant advancement in the ongoing and perpetual evolution of minimally invasive surgery and is demonstrative of Teleflex’s unwavering commitment to innovation.
“We are encouraged by surgeons’ enthusiastic response to our percutaneous surgical devices and are optimistic the new Percuvance System will become a new standard of care in laparoscopic surgery.”
The first-generation Percuvance System which was launched in 2015 was used by more than 150 surgeons in the US.
Its maker Teleflex is a global medical device provider in the critical care and surgery segment and is headquartered in Wayne in the US state of Pennsylvania.
